Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Drug Licensed for Precision Autism Spectrum Therapies

Brain activity graphic

A company making precision therapies for neurological disorders is acquiring rights to a compound first designed as a treatment for cancer, inflammation, and oxidative stress. . . . → Read More: Drug Licensed for Precision Autism Spectrum Therapies

Infographic – Sharp Drop in Q3 Venture Funds

Global venture funding Q3 2022

Total venture investing worldwide dropped to $81 billion in July to September 2022, a decline of $40 billion or one-third compared to the second quarter of the year. . . . → Read More: Infographic – Sharp Drop in Q3 Venture Funds

RNA Cancer Immunotherapy Shown Feasible in Preclinical Test

Lung cancer illustration

Tests with lab animals show synthetic viral RNA particles, encased in natural oils, can safely invoke an immune response to attack solid tumors. . . . → Read More: RNA Cancer Immunotherapy Shown Feasible in Preclinical Test

Nasal Spray Vaccines Get CEPI, NIH Funding

Nasal spray

A developer of infectious disease vaccines is gaining funds for new nasal sprays protecting against a range of coronaviruses and the sexually-transmitted disease gonorrhea. . . . → Read More: Nasal Spray Vaccines Get CEPI, NIH Funding

Yom Kippur 5783

Shofar

Regular posting will resume tomorrow, Thursday, 6 Oct. . . . → Read More: Yom Kippur 5783

Algae-Grown Non-Needle Malaria Vaccine in Preclinical Test

Malaria clinic

A vaccine grown in genetically-altered algae, designed as a nasal-spray and edible drug, is shown to protect lab mice against parasite infections causing malaria. . . . → Read More: Algae-Grown Non-Needle Malaria Vaccine in Preclinical Test

Patent Issued for Crispr-Edited Viruses in Microbiome

Crispr-Cas9

A biotechnology company developing gene-edited therapies for bacterial infections in the gut received a U.S. patent for viruses engineered as treatments. . . . → Read More: Patent Issued for Crispr-Edited Viruses in Microbiome

Infographic – Biotech Index Q3 Rollercoaster

NBI Year to date 30 Sept 2022

For the year-to-date, as noted in today’s chart, NBI shows a general decline, losing more than one-fifth of its value since January. . . . → Read More: Infographic – Biotech Index Q3 Rollercoaster